HRP20041188A2 - N-supstituirani triciklički 3-aminopirazoli kao inhibitori pdfg receptora - Google Patents

N-supstituirani triciklički 3-aminopirazoli kao inhibitori pdfg receptora

Info

Publication number
HRP20041188A2
HRP20041188A2 HR20041188A HRP20041188A HRP20041188A2 HR P20041188 A2 HRP20041188 A2 HR P20041188A2 HR 20041188 A HR20041188 A HR 20041188A HR P20041188 A HRP20041188 A HR P20041188A HR P20041188 A2 HRP20041188 A2 HR P20041188A2
Authority
HR
Croatia
Prior art keywords
aminopyrazoles
substituted tricyclic
receptor inhibitors
pdfg
compounds
Prior art date
Application number
HR20041188A
Other languages
English (en)
Croatian (hr)
Inventor
Yung Ho Chih
Anders Brunmark Bengt
Emanuel Stuart
A. Galemmo Robert Jr.
L. Johnson Dana
W. Ludovici Donald
Maharoof Umar
M. Mei Jay
L. Sechler Jan
D. Strobel Eric
W. Tuman Robert
Kwo Yen Hwa
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HRP20041188A2 publication Critical patent/HRP20041188A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Materials For Medical Uses (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
HR20041188A 2002-05-15 2003-05-13 N-supstituirani triciklički 3-aminopirazoli kao inhibitori pdfg receptora HRP20041188A2 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38073502P 2002-05-15 2002-05-15
PCT/US2003/015193 WO2003097609A1 (en) 2002-05-15 2003-05-13 N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors

Publications (1)

Publication Number Publication Date
HRP20041188A2 true HRP20041188A2 (hr) 2007-03-31

Family

ID=29550005

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20041188A HRP20041188A2 (hr) 2002-05-15 2003-05-13 N-supstituirani triciklički 3-aminopirazoli kao inhibitori pdfg receptora

Country Status (29)

Country Link
US (2) US7196110B2 (es)
EP (1) EP1506175B1 (es)
JP (1) JP2006502097A (es)
KR (1) KR20040106554A (es)
CN (1) CN100396670C (es)
AR (1) AR040079A1 (es)
AT (1) ATE427301T1 (es)
AU (1) AU2003234567A1 (es)
BR (1) BRPI0311179A2 (es)
CA (1) CA2486097A1 (es)
CR (1) CR7574A (es)
DE (1) DE60326950D1 (es)
EA (1) EA008770B1 (es)
ES (1) ES2323952T3 (es)
HR (1) HRP20041188A2 (es)
IL (1) IL165197A0 (es)
MX (1) MXPA04011320A (es)
MY (1) MY138268A (es)
NO (1) NO20045451L (es)
NZ (1) NZ548796A (es)
PE (1) PE20040758A1 (es)
PL (1) PL374062A1 (es)
RS (1) RS98804A (es)
SA (1) SA03240431A (es)
TW (1) TW200407311A (es)
UA (1) UA80820C2 (es)
UY (1) UY27811A1 (es)
WO (1) WO2003097609A1 (es)
ZA (1) ZA200410108B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003234567A1 (en) * 2002-05-15 2003-12-02 Janssen Pharmaceutica N.V. N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors
CN1914179A (zh) * 2003-11-13 2007-02-14 詹森药业有限公司 用于生物分子靶标识别的固定的n－取代的三环3－氨基吡唑类
US20050153371A1 (en) * 2004-01-07 2005-07-14 Ambit Biosciences Corporation Conjugated small molecules
DK1794313T3 (da) * 2004-06-21 2013-07-22 Proteome Sciences Plc Fremgangsmåde til screeninger der anvender C-ABL, FYN og SYK i kombination med tau-protein
WO2006010127A2 (en) 2004-07-09 2006-01-26 Medisyn Technologies, Inc. Therapeutic compound and treatments
EP1799659A1 (en) 2004-10-13 2007-06-27 PTC Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
JP2006321724A (ja) * 2005-05-17 2006-11-30 Tokyo Univ Of Science 抗腫瘍剤
WO2007149827A2 (en) * 2006-06-20 2007-12-27 Janssen Pharmaceutica, N.V. Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
US20080031866A1 (en) * 2006-06-20 2008-02-07 Eichenbaum Gary M Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
WO2008094896A1 (en) * 2007-01-31 2008-08-07 Janssen Pharmaceutica, N.V. N-substituted tricyclic 3-aminopyrazoles as anti-mitotic tubulin polymerization inhibitors
US9220837B2 (en) 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
MX2009010000A (es) 2007-03-19 2010-03-17 Insuline Medical Ltd Dispositivo para el suministro de farmaco.
US8409133B2 (en) 2007-12-18 2013-04-02 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
CA2743027C (en) 2008-11-07 2016-04-12 Insuline Medical Ltd. Device and method for drug delivery
JP5728487B2 (ja) * 2009-10-29 2015-06-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 三環式ヘテロ環化合物
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
JPWO2012121168A1 (ja) * 2011-03-04 2014-07-17 国立大学法人京都大学 キナーゼ阻害剤
TWI553010B (zh) * 2012-04-12 2016-10-11 財團法人生物技術開發中心 雜環吡唑化合物，其製備方法及用途
ES2704744T3 (es) 2012-06-13 2019-03-19 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9475816B2 (en) 2012-09-07 2016-10-25 Takeda Pharmaceutical Company Limited Substituted-1,4-dihydropyrazolo[4,3-b]indoles
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
SG11201507255QA (en) * 2013-03-14 2015-10-29 Newlink Genetics Corp Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CN105884828A (zh) * 2015-02-16 2016-08-24 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MX373169B (es) 2015-02-20 2020-04-24 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
ES2859478T3 (es) 2016-09-02 2021-10-04 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos sustituidos
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US11046646B2 (en) 2017-08-09 2021-06-29 Bristol-Myers Squibb Company Alkylphenyl compounds
WO2019032631A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company Oxime ether compounds
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TWI759829B (zh) * 2019-08-23 2022-04-01 財團法人生物技術開發中心 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3237696A1 (en) 2021-11-08 2023-05-11 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
CN114890987B (zh) * 2022-04-13 2023-12-19 万华化学集团股份有限公司 一种硫酚-噻吩配体及其制备方法、烯烃聚合催化剂及其制备方法、应用
CN114686427B (zh) * 2022-05-23 2022-07-29 中国人民解放军总医院第一医学中心 一种脾脏调节型b淋巴细胞及其制备方法与应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928378A (en) 1974-01-30 1975-12-23 Hoechst Co American Fused bicyclic aminopyrazoles
US4220776A (en) 1978-12-21 1980-09-02 E. I. Du Pont De Nemours And Company N-(Pyridothienopyrazol)amides
US4140785A (en) 1978-05-08 1979-02-20 E. I. Du Pont De Nemours And Company N-(benzothienopyrazol)amide antirhinoviral agents
US4420476A (en) 1982-05-24 1983-12-13 Averst McKenna & Harrison, Inc. Benzofuro[3,2-c]pyrazol-3-amine derivatives
US5409930A (en) 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
JPH0622109A (ja) 1992-07-03 1994-01-28 Fujitsu Ltd ファクシミリ装置およびファクシミリ情報サービス方式
JPH06100561A (ja) 1992-07-13 1994-04-12 Otsuka Pharmaceut Factory Inc ナフチリジン及びピリドピラジン誘導体
JP2997828B2 (ja) 1992-07-30 2000-01-11 株式会社大塚製薬工場 キノリン及びナフチリジン誘導体
JP3148960B2 (ja) 1993-04-12 2001-03-26 コニカ株式会社 写真用シアンカプラー
ES2126773T3 (es) 1993-09-15 1999-04-01 Merck Sharp & Dohme Derivados triciclicos heteroaromaticos condensados como ligandos de subtipos de receptores de dopamina.
US5364881A (en) 1993-11-15 1994-11-15 The Medical College Of Wisconsin Research Foundation, Inc. S-alkyl-isothioureido-amino acids and use thereof
JP3245765B2 (ja) 1994-07-05 2002-01-15 コニカ株式会社 写真用シアンカプラー
US5476932A (en) 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
US5476851A (en) 1994-09-08 1995-12-19 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Pyrazolo[3,4-g]quinoxaline compounds which inhibit PDGF receptor protein tyrosine kinase
US5563173A (en) 1994-12-22 1996-10-08 Research Development Foundation Anti-proliferative effects of sodium butyrate
DE69623455T2 (de) 1995-04-19 2003-01-16 Schneider (Usa) Inc., Plymouth Beschichteter dilatator zur abgabe eines arzneistoffs
CN1278724A (zh) 1997-10-06 2001-01-03 巴斯福股份公司 抑制酪氨酸激酶活性的茚并[1,2－c]吡唑衍生物
JP2001518501A (ja) * 1997-10-06 2001-10-16 ビーエーエスエフ アクチェンゲゼルシャフト インデノ［１，２−ｃ］−、ナフト［１，２−ｃ］−およびベンゾ［６，７］シクロへプタ［１，２−ｃ］ピラゾール誘導体
JP4194678B2 (ja) 1997-11-28 2008-12-10 キリンファーマ株式会社 キノリン誘導体およびそれを含む医薬組成物
US5932580A (en) 1997-12-01 1999-08-03 Yissum Research And Development Company Of The Hebrew University Of Jerusalem PDGF receptor kinase inhibitory compounds their preparation and compositions
DE69940951D1 (de) 1998-04-21 2009-07-16 Bristol Myers Squibb Pharma Co Nd wachstumshemmende mittel
WO2000007996A2 (en) 1998-08-07 2000-02-17 Chiron Corporation Pyrazoles as estrogen receptor modulators
CN1368970A (zh) * 1999-04-06 2002-09-11 克诺尔股份有限公司 作为酪氨酸激酶抑制剂的取代的1,4－二氢茚并[1,2－c]吡唑
EP1179541B1 (en) 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
US6824987B1 (en) 1999-05-11 2004-11-30 President And Fellows Of Harvard College Small molecule printing
JP2004501083A (ja) * 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド プロテインキナーゼを阻害するためのピラゾール
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
ES2349762T3 (es) 2000-08-10 2011-01-11 Pfizer Italia S.R.L. Biciclo-pirazoles activos como inhibidores de quinasas, procedimientos para su preparación y composiciones farmacéuticas que los comprenden.
AU2003234567A1 (en) * 2002-05-15 2003-12-02 Janssen Pharmaceutica N.V. N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors

Also Published As

Publication number Publication date
NO20045451L (no) 2005-02-09
UY27811A1 (es) 2003-10-31
AR040079A1 (es) 2005-03-16
EP1506175A1 (en) 2005-02-16
US7795440B2 (en) 2010-09-14
ATE427301T1 (de) 2009-04-15
BRPI0311179A2 (pt) 2016-06-21
CN100396670C (zh) 2008-06-25
PE20040758A1 (es) 2005-01-01
WO2003097609A1 (en) 2003-11-27
EP1506175B1 (en) 2009-04-01
SA03240431A (ar) 2005-12-03
US20040082639A1 (en) 2004-04-29
KR20040106554A (ko) 2004-12-17
TW200407311A (en) 2004-05-16
US7196110B2 (en) 2007-03-27
MY138268A (en) 2009-05-29
ZA200410108B (en) 2006-05-31
JP2006502097A (ja) 2006-01-19
US20070142305A1 (en) 2007-06-21
AU2003234567A1 (en) 2003-12-02
EA008770B1 (ru) 2007-08-31
IL165197A0 (en) 2005-12-18
CA2486097A1 (en) 2003-11-27
DE60326950D1 (de) 2009-05-14
MXPA04011320A (es) 2005-08-16
CN1668601A (zh) 2005-09-14
NZ548796A (en) 2008-01-31
PL374062A1 (en) 2005-09-19
UA80820C2 (en) 2007-11-12
CR7574A (es) 2008-09-10
EA200401378A1 (ru) 2005-06-30
ES2323952T3 (es) 2009-07-28
RS98804A (sr) 2006-10-27

Similar Documents

Publication Publication Date Title
HRP20041188A2 (hr) N-supstituirani triciklički 3-aminopirazoli kao inhibitori pdfg receptora
MX2022000854A (es) Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr.
ID27535A (id) Turunan pirasola sebagai inhibitor p-38 map kinase
WO2009132774A8 (en) New substituted indolin-2-one derivatives and their use as p38 mitogen-activated kinase inhibitors
GEAP202015169A (en) Tyrosine amide derivatives as rho-kinase inhibitors
ATE554087T1 (de) Neue kinaseinhibitoren
MX2009002377A (es) Derivados de indazol como moduladores de cinasa asociados con el receptor de interleucina-1.
EA202090413A1 (ru) Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы
ATE532781T1 (de) 5-(acylamino)indazol-derivate als kinase- inhibitoren
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
NO20065727L (no) Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter
NO20071619L (no) Fremgangsmate for fremstilling av indazol forbindelse
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
NO20072795L (no) Pyrazol [1,5-a]pyrimidiner som er nyttige som inhibitorer av proteinkinaser
DE602004011199D1 (de) 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren
DK1791830T3 (da) Diaminotriazol-forbindelser der er nyttige som protein-kinase-inhibitorer
EA200500299A1 (ru) Пиразольные композиции, используемые в качестве ингибиторов gsk-3
MY156727A (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
MX2008005398A (es) Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer.
EA201300080A1 (ru) Дипиридильные производные, пригодные для лечения заболеваний, индуцированных киназами
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
EA202091475A1 (ru) ПРОИЗВОДНЫЕ 5-(2-(2,5-ДИФТОРФЕНИЛ)ПИРРОЛИДИН-1-ИЛ)-3-(1H-ПИРАЗОЛ-1-ИЛ)ПИРАЗОЛО[1,5-а]ПИРИМИДИНА И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
EA201001481A1 (ru) Производные третичного амина в качестве ингибиторов фосфодиэстеразы-4

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20090511

Year of fee payment: 7

OBST Application withdrawn